Franck Atienzar

Dr. Franck Atienzar


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
FAFranck Atienzar
Franck Atienzar
KTKaren Tilmant
Karen Tilmant
HGHelga H. Gerets
Helga H. Gerets
GTGaelle Toussaint
Gaelle Toussaint
SSSebastien Speeckaert
Sebastien Speeckaert
SDStephane Dhalluin
Stephane Dhalluin
The use of impedance-based label-free technology applied to drug discovery is nowadays receiving more and more attention. Indeed, such a simple and noninvasive assay that interferes minimally with cell morphology and function allows one to perform kinetic measurements and to obtain information on proliferation, migration, cytotoxicity, and receptor-mediated signaling. The objective of the study was to further assess the usefulness of a real-time cell analyzer (RTCA) platform based on impedance in the context of quality control and data reproducibility. The data indicate that this technology is useful to determine the best coating and cellular density conditions for different adherent cellular models including hepatocytes, cardiomyocytes, fibroblasts, and hybrid neuroblastoma/neuronal cells. Based on 31 independent experiments, the reproducibility of cell index data generated from HepG2 cells exposed to DMSO and to Triton X-100 was satisfactory, with a coefficient of variation close to 10%. Cell index data were also well reproduced when cardiomyocytes and fibroblasts were exposed to 21 compounds three times (correlation >0.91, p < 0.0001). The data also show that a cell index decrease is not always associated with cytotoxicity effects and that there are some confounding factors that can affect the analysis. Finally, another drawback is that the correlation analysis between cellular impedance measurements and classical toxicity endpoints has been performed on a limited number of compounds. Overall, despite some limitations, the RTCA technology appears to be a powerful and reliable tool in drug discovery because of the reasonable throughput, rapid and efficient performance, technical optimization, and cell quality control.

5 September 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
FAFranck Atienzar
Franck Atienzar
EBEric A. Blomme
Eric A. Blomme
Minjun ChenMinjun Chen
Minjun Chen
PHPhilip Hewitt
Philip Hewitt
JKJ. Gerry Kenna
J. Gerry Kenna
DDDonna M. Dambach
Donna M. Dambach
Drug-induced liver injury (DILI) is a major cause of late-stage clinical drug attrition, market withdrawal, black-box warnings, and acute liver failure. Consequently, it has been an area of focus for toxicologists and clinicians for several decades. In spite of considerable efforts, limited improvements in DILI prediction have been made and efforts to improve existing preclinical models or develop new test systems remain a high priority. While prediction of intrinsic DILI has improved, identifying compounds with a risk for idiosyncratic DILI (iDILI) remains extremely challenging because of the lack of a clear mechanistic understanding and the multifactorial pathogenesis of idiosyncratic drug reactions. Well-defined clinical diagnostic criteria and risk factors are also missing. This paper summarizes key data interpretation challenges, practical considerations, model limitations, and the need for an integrated risk assessment. As demonstrated through selected initiatives to address other types of toxicities, opportunities exist however for improvement, especially through better concerted efforts at harmonization of current, emerging and novel in vitro systems or through the establishment of strategies for implementation of preclinical DILI models across the pharmaceutical industry. Perspectives on the incorporation of newer technologies and the value of precompetitive consortia to identify useful practices are also discussed.

1 February 2014 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
FAFranck Atienzar
Franck Atienzar
ENEric I. Novik
Eric I. Novik
HGHelga H. Gerets
Helga H. Gerets
APAmit Parekh
Amit Parekh
CDClaude Delatour
Claude Delatour
SDStéphane Dhalluin
Stéphane Dhalluin

15 March 2013 in Biosensors
Verified
Journal Article
Open access
PDF file
FAFranck Atienzar
Franck Atienzar
HGHelga Gerets
Helga Gerets
KTKaren Tilmant
Karen Tilmant
GTGaëlle Toussaint
Gaëlle Toussaint
SDStéphane Dhalluin
Stéphane Dhalluin
The use of label-free technologies based on electrical impedance is becoming more and more popular in drug discovery. Indeed, such a methodology allows the continuous monitoring of diverse cellular processes, including proliferation, migration, cytotoxicity and receptor-mediated signaling. The objective of the present study was to further assess the usefulness of the real-time cell analyzer (RTCA) and, in particular, the xCELLigence platform, in the context of early drug development for pharmacology and toxicology investigations. In the present manuscript, four cellular models were exposed to 50 compounds to compare the cell index generated by RTCA and cell viability measured with a traditional viability assay. The data revealed an acceptable correlation (ca. 80%) for both cell lines (i.e., HepG2 and HepaRG), but a lack of correlation (ca. 55%) for the primary human and rat hepatocytes. In addition, specific RTCA profiles (signatures) were generated when HepG2 and HepaRG cells were exposed to calcium modulators, antimitotics, DNA damaging and nuclear receptor agents, with a percentage of prediction close to 80% for both cellular models. In a subsequent experiment, HepG2 cells were exposed to 81 proprietary UCB compounds known to be genotoxic or not. Based on the DNA damaging signatures, the RTCA technology allowed the detection of ca. 50% of the genotoxic compounds (n = 29) and nearly 100% of the non-genotoxic compounds (n = 52). Overall, despite some limitations, the xCELLigence platform is a powerful and reliable tool that can be used in drug discovery for toxicity and pharmacology studies.

25 October 2011 in BMC Genomics
Verified
Journal Article
Open access
PDF file
YLYann Landkocz
Yann Landkocz
PPPascal Poupin
Pascal Poupin
FAFranck Atienzar
Franck Atienzar
PVPaule Vasseur
Paule Vasseur
Di-(2-ethylhexyl)-phthalate (DEHP) is a commonly used plasticizer in polyvinylchloride (PVC) formulations and a potentially non-genotoxic carcinogen. The aim of this study was to identify genes whose level of expression is altered by DEHP by using a global wide-genome approach in Syrian hamster embryo (SHE) cells, a model similar to human cells regarding their responses to this type of carcinogen. With mRNA Differential Display (DD), we analysed the transcriptional regulation of SHE cells exposed to 0, 12.5, 25 and 50 μM of DEHP for 24 hrs, conditions which induced neoplastic transformation of these cells. A real-time quantitative polymerase chain reaction (qPCR) was used to confirm differential expression of genes identified by DD.

21 March 2018
Verified
Book Chapter
Closed access
PDF file
FAFranck Atienzar
Franck Atienzar
JNJean-Marie Nicolas
Jean-Marie Nicolas